A designed inhibitor of a CLC antiporter blocks function through a unique binding mode
Andrew E Howery1, Shelley Elvington, Sherwin J Abraham
1Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.
Chemistry & Biology
|November 27, 2012
Summary
Researchers developed a novel small-molecule inhibitor, OADS, targeting CLC antiporters but not channels. This discovery aids in understanding ion transport mechanisms and developing treatments for CLC-related disorders.
Area of Science:
- Biochemistry
- Molecular Biology
- Biophysics
Background:
- Anion-selective transporters and channels are crucial for cellular function, but small-molecule inhibitors are lacking.
- The Chloride channel (CLC) family exhibits diverse functions, including passive transport and secondary-active transport.
- Understanding CLC antiporter and channel mechanisms is vital for biomedical research.
Purpose of the Study:
- To synthesize and characterize a specific small-molecule inhibitor for CLC antiporters.
- To investigate the inhibitory mechanism and specificity of the novel compound.
- To provide a tool for elucidating differences between CLC antiporter and channel functions.
Main Methods:
- Chemical synthesis of 4,4 -octanamidostilbene-2,2 -disulfonate (OADS).
- Biochemical and biophysical characterization of OADS.
- Inhibition assays using CLC antiporter (ClC-ec1) and CLC channel (ClC-1).
Main Results:
- OADS selectively inhibits the CLC-ec1 antiporter with low micromolar affinity.
- OADS shows no specific inhibitory effect on the CLC-1 channel.
- Inhibition of ClC-ec1 involves binding to two distinct intracellular sites, with lipid-dependent effects.
Conclusions:
- OADS is a valuable tool for differentiating CLC antiporter and channel mechanisms.
- The compound's binding sites and lipid dependence offer insights into antiporter function.
- This inhibitor can advance research into CLC-mediated disorders and therapeutic development.
More Related Videos
Related Concept Videos
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
02:34Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...